Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Payables (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Payables for 16 consecutive years, with $124000.0 as the latest value for Q4 2025.

  • Quarterly Payables rose 14.81% to $124000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $124000.0 through Dec 2025, up 14.81% year-over-year, with the annual reading at $124000.0 for FY2025, 14.81% up from the prior year.
  • Payables for Q4 2025 was $124000.0 at Gyre Therapeutics, down from $556000.0 in the prior quarter.
  • The five-year high for Payables was $7.7 million in Q4 2022, with the low at $5000.0 in Q2 2023.
  • Average Payables over 5 years is $1.5 million, with a median of $316500.0 recorded in 2024.
  • The sharpest move saw Payables tumbled 99.66% in 2023, then soared 5320.0% in 2024.
  • Over 5 years, Payables stood at $6.4 million in 2021, then rose by 19.64% to $7.7 million in 2022, then plummeted by 95.38% to $355000.0 in 2023, then plummeted by 69.58% to $108000.0 in 2024, then rose by 14.81% to $124000.0 in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $124000.0, $556000.0, and $71000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.